Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $72.92 +1.42%
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $39.4 million versus the consensus estimate of $28.82 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
- PSQ Holdings announces 1-for-15 reverse stock split effective July 13
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
